REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy
Conference paper > Summary Text · 2014
Authors: Maurice Perol, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay GÖKSEL, Keunchli Park, Ruben Carlo Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey Oriov, Conrad R. Lewanski, Ekaterine Alexandris, Annemaria Zimmerman, Nadia Chouaki, William J. John, Sergey Yurasov, Edward B. Garon
50th Annual Meeting of the American-Society-of-Clinical-Oncology, United States Of America, International, Verbal, Summary Text, 2014-2014, WoS, vol 32